Montana has taken a dramatic step into uncharted regulatory territory, enacting legislation that allows biotechnology companies to sell experimental drugs that have only passed through the earliest stages of human testing. Under the new framework, firms whose treatments have been trialed in as few as ten healthy individuals can pay a $12,500 application fee to a newly established state review board. Once approval is granted, these drugs can be marketed and sold through specialized experimental treatment clinics, with the first such facility expected to open its doors by the end of this year.
This move represents the most aggressive expansion of the “right to try” movement in the United States. Unlike federal right-to-try laws, which permit terminally ill patients to access unapproved treatments directly from manufacturers without FDA oversight, Montana’s statute goes further by creating a formal, state-sanctioned commercial pathway. The law theoretically extends access to any individual who can provide informed consent and, critically, can afford to pay. For patients and families clinging to hope where conventional medicine has offered little, this is a seismic shift. For medical ethicists and public health officials, it is a gamble that blurs the line between innovation and exploitation.
Montana pushes forward experimental drug sales with a novel regulatory model
The core mechanism of Montana’s plan is the creation of a state-level review board that acts as a gatekeeper, albeit one with a significantly lower bar than the Food and Drug Administration. This board, which companies must petition for a fee of $12,500, is tasked with evaluating whether a drug has completed what the law defines as preliminary safety testing. The key detail here is the “preliminary” nature of the requirement. The FDA typically demands rigorous, multi-phase clinical trials involving hundreds or thousands of patients to establish both safety and efficacy before a drug can be marketed. Montana’s board will operate on a far more compressed and less demanding standard, potentially approving treatments that have only been observed in a handful of healthy volunteers over a short period.
How does Montana’s right-to-try law differ from existing federal law?
The federal Right to Try Act, signed into law in 2018, allows patients with life-threatening illnesses to request access to investigational drugs that have completed a Phase 1 clinical trial and are still under active development for FDA approval. Crucially, it does not permit companies to sell these drugs; they must be provided for free. Montana’s law fundamentally changes this dynamic by creating a commercial market. Companies can charge for their experimental treatments, and the law applies to a broader population, not just those who are terminally ill. This commercial element introduces powerful financial incentives that critics argue could encourage companies to bypass rigorous testing in favor of faster, profit-driven sales. The state’s board effectively becomes a substitute for the FDA’s standard approval process, creating a parallel regulatory track within Montana’s borders.
The desperation behind the legislation: A father’s search for a cure
The human story at the heart of this legislative push is embodied by Kris DeVault and his son, Brody. Born in March 2023, Brody was diagnosed with creatine transporter deficiency, a rare genetic condition that starves the brain and muscles of the energy required for normal development. Currently, there are no approved cures or treatments for this devastating disorder. DeVault has identified a biotechnology company developing an experimental drug that might address the underlying deficiency. However, this drug remains in the earliest stages of development, having only been tested in animals and a small cohort of healthy adults. Under standard FDA regulations, it is completely inaccessible to Brody.
For DeVault, Montana’s new law represents a lifeline. He is acutely aware that the drug may not work, or that it could even cause harm. But faced with the certainty of his son’s condition progressing without any intervention, the calculated risk of an unproven treatment feels preferable to the inaction mandated by the current system. His story illustrates the profound moral calculus that right-to-try laws force: the right of an individual to choose a potentially ineffective or dangerous treatment when no other options exist, weighed against the broader societal commitment to protecting patients from unsafe medical products. DeVault is not alone in his pursuit; he represents a growing community of patients and families who are increasingly willing to bypass the traditional medical establishment in search of any possible remedy.
What are the risks of Montana’s experimental drug sales plan?
The dangers inherent in Montana’s approach are substantial and multifaceted. The most immediate risk is to patient safety. Drugs that have only been tested in a small number of healthy volunteers have not been evaluated for their effects in diverse patient populations, particularly those who are already ill and may be taking other medications. Side effects that emerge only in larger, more diverse groups, or that manifest only after prolonged use, will remain entirely unknown. Patients could suffer serious adverse reactions, including organ damage, disability, or death, from a drug that was never properly vetted for their specific circumstances. The informed consent process, while legally and ethically necessary, may be insufficient to convey the true magnitude of these unknown risks to desperate patients and their families.
Beyond direct patient harm, the law creates a problematic incentive structure for the biotech industry. By offering a streamlined, paid path to market within a single state, Montana could attract companies with marginal or poorly designed preliminary data who are eager to generate revenue before completing—or even undertaking—the expensive and time-consuming large-scale trials that the FDA requires. This could divert resources and attention away from rigorous scientific investigation and toward marketing and sales. It also raises significant questions about liability. If a patient is harmed or dies as a result of treatment received under this law, who bears legal responsibility? The company? The state review board? The clinic? The patient? The legislation’s framework around these crucial questions remains a source of intense debate.
What is the position of the longevity community on this law?
Within the longevity and life-extension communities, Montana’s law is being hailed as a potentially revolutionary development. For individuals who view aging itself as a disease to be treated and who are frustrated by the slow pace of traditional drug development, the ability to access and pay for early-stage anti-aging interventions is an exciting prospect. They argue that the current regulatory system is too conservative, delaying access to potentially life-saving therapies for years or even decades. From their perspective, Montana’s model respects individual autonomy and accelerates the pace of medical innovation by allowing willing participants to bear the risk of early-stage treatments. They see it as a laboratory for a more flexible, patient-driven approach to medical regulation that could, if successful, be adopted by other states or even influence federal policy. This perspective, however, stands in stark opposition to the caution voiced by mainstream medical and public health authorities, who see it as a dangerously deregulated experiment that prioritizes hope over evidence.
The broader implications for the future of medical regulation
Montana’s initiative is not occurring in a vacuum. It is the latest and most aggressive salvo in a long-running debate about the balance between patient access and safety in the American healthcare system. The federal right-to-try movement was itself a reaction to the perceived slowness of the FDA, particularly for patients with terminal illnesses. Montana’s law takes that impulse and magnifies it, removing the terminal illness requirement and adding a commercial element. If the clinics in Montana prove to be financially viable and attract a steady stream of patients, other states could follow suit, potentially creating a patchwork of conflicting regulatory standards across the country. This could put pressure on the FDA to adapt its own processes or risk seeing its authority eroded state by state.
The long-term implications extend beyond just drug approval. The success or failure of Montana’s experiment will be closely watched by the entire medical and biotechnology ecosystem. A catastrophic outcome—a series of patient deaths or severe injuries linked to drugs sold under this law—could set back the right-to-try movement significantly and reinforce the importance of the FDA’s gatekeeping role. Conversely, if patients report benefits from treatments they could not otherwise access, and if the state board is able to effectively manage risks, the model could gain momentum as a viable alternative pathway for bringing certain types of therapies to market more quickly. The technology community, particularly those invested in AI-driven drug discovery and personalized medicine, will be tracking this closely, as the model could offer a faster route to commercialization for their innovations.
What happens if an experimental drug causes harm in Montana?
This question is the central, unresolved dilemma of the entire enterprise. The legal and ethical protections for patients who suffer harm under this new system are unclear. The informed consent document that patients sign will almost certainly contain waivers releasing the company, the clinic, and potentially the state from liability. This shifts the entire financial and medical burden of any adverse event squarely onto the patient or their family. In a standard clinical trial, the sponsoring company is typically responsible for providing medical care for injuries that occur as a direct result of the experimental treatment, and the trial is covered by insurance. Under Montana’s commercial model, the patient is a customer purchasing an unproven product. If that product causes injury, the patient’s recourse is limited, and the cost of treating those injuries would fall on their personal health insurance—if they have it—or on public safety-net programs. This could create a situation where the most vulnerable patients bear the highest financial and health risks.
A forward-looking analysis of Montana’s medical hub
Montana is positioning itself as a maverick in American healthcare, a state willing to challenge federal orthodoxy in the name of providing hope and fostering innovation. The first clinics are expected to open around the end of the year, and they will become ground zero for this bold and deeply controversial experiment. The world will be watching to see if Montana can become a legitimate hub for early-stage medical breakthroughs or if it becomes a cautionary tale about the limits of deregulation. For the Kris DeVaults of the world, the promise of a treatment, no matter how unproven, is worth the risk. The coming months and years will reveal whether that faith is rewarded or whether the state’s ambition outpaces its ability to protect the very people it seeks to help. The ultimate test will not be legislative, but clinical and ethical: will this law lead to genuine medical advances for patients who have no other options, or will it create a marketplace of false hope where financial desperation and scientific uncertainty converge with dangerous consequences? The answer will define the future of patient access in America for a generation.
